Will St. Jude Medical (STJ) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:32PM CDT
Our proven model does not conclusively show that St. Jude Medical is likely to beat earnings this quarter.
Omeros to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Mon Apr 07, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 13th Annual Needham Healthcare Conference in New York later this week. The presentation is scheduled for Wednesday, April 9, 2014 at 3:00 p.m. EDT.
Morning Movers in Biotech: Medicines Co., Omeros Corporation, Opko Health, Inc. and VIVUS, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Apr 03, 8:03AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for The Medicines Company , Omeros Corp. , Opko Health and VIVUS, . FDA accepts The Medicines Company's Biologic License Application for Fibrocaps ...
Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
PR Newswire - Thu Apr 03, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that its Investigational New Drug Application (IND) to evaluate OMS721 for the inhibition of complement--mediated thrombotic microangiopathies (TMAs) has been cleared by the U.S. Food and Drug Administration (FDA). OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. Omeros announced last year that the FDA granted OMS721 Orphan Drug designation for the inhibition of complement--mediated TMAs, a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain.
Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference
PR Newswire - Tue Apr 01, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) to make an oral presentation on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition. The SIRS Conference will take place in Florence, Italy April 5-9. The Omeros presentation is entitled "Early Clinical Results of the Phosphodiesterase 10 Inhibitor OMS643762 in Development for the Treatment of Schizophrenia and Huntington's Disease" and is scheduled for Sunday April 6 during the pharmaceutical pipeline session. OMS643762 is the reference name for OMS824 in the company's clinical development program.
Lawsuits, Clinical Studies, Financial Results, and Stock Movements - Analyst Notes on Idenix, BG Medicine, Progenics, Omeros, and Opexa
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), BG Medicine, Inc. (NASDAQ: BGMD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Omeros Corporation (NASDAQ: OMER), and Opexa Therapeutics, Inc. (NASDAQ: OPXA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register http://www.analystsreview.com/register
Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference
PR Newswire - Fri Mar 21, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the BioCentury Future Leaders in the Biotech Industry Conference in New York next week. The presentation is scheduled for Friday, March 28, 2014 at 9:00 a.m. EDT.
Omeros Closes $40.25 Million Public Offering of Common Stock
PR Newswire - Wed Mar 19, 4:19PM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on March 14, 2014, relating to the sale of 3,500,000 shares of its common stock at a price of $11.50 per share for gross proceeds of approximately $40.25 million. The closing included the sale of 456,521 shares of common stock sold pursuant to the overallotment option granted by Omeros to the underwriters, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $37.8 million.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 14, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Omeros Corporation Shares Sank
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 14, 12:06PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros , a clinical-stage...
Omeros Prices $35.0 Million Public Offering of Common Stock
PR Newswire - Fri Mar 14, 7:33AM CDT
Omeros Corporation (NASDAQ: OMER) today announced that it has priced an underwritten public offering of 3,043,479 shares of its common stock at a price to the public of $11.50 per share for gross proceeds of $35.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses, will be approximately $32.8 million. Omeros has also granted the underwriters a 30-day option to purchase up to an additional 456,521 shares of common stock to cover overallotments, if any, which would result in additional gross proceeds of approximately $5.2 million if exercised in full.
Omeros Announces Proposed Public Offering of Common Stock
PR Newswire - Thu Mar 13, 3:36PM CDT
Omeros Corporation (NASDAQ: OMER) today announced its intention to offer, subject to market and other conditions, shares of its common stock in a registered underwritten public offering. Omeros also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering solely to cover overallotments, if any.
Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results
PR Newswire - Thu Mar 13, 3:16PM CDT
Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and financial results for the fourth quarter and year ended December 31, 2013, which include:
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
PR Newswire - Mon Mar 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. In February, Omeros reported positive results from its OMS721 Phase 1 clinical trial and, earlier this month, announced submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial in patients with TMA, including patients with aHUS.
Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
PR Newswire - Thu Mar 06, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the previously reported highest dose and had a similar side-effect profile to those of the lower doses. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds
PR Newswire - Wed Mar 05, 7:52AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which is expected to fund later today. The new credit facility consists of a $32 million term loan, which requires interest-only payments through March 2015. Thereafter, monthly principal and interest payments will be due through the March 2018 maturity date. The company will use a portion of the loan proceeds to repay its obligations under its prior loan and security agreement with Oxford Finance and affiliates, and the remaining net proceeds of approximately $12.6 million will be used for general corporate purposes and working capital.
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 04, 8:06AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at three health care stocks -- ...